Business Context and Reporting Period
This Form 8-K reports on the results of the PAVmed Inc. 2019 Annual Meeting of Stockholders held on June 26, 2019. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Stockholders approved five key proposals at the annual meeting:
- Director Elections: Lishan Aklog, M.D., and Michael J. Glennon were re-elected as Class C directors.
- Authorized Share Increase: The Certificate of Incorporation was amended to increase authorized common stock from 75,000,000 to 100,000,000 shares.
- Share Issuance Approval: Stockholders approved the issuance of shares to Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, related to a transaction completed on December 27, 2018, to satisfy Nasdaq Listing Rule 5635.
- Equity Plan Amendment: The 2014 Long-Term Incentive Equity Plan was amended to increase available shares by 2,000,000, from 5,951,081 to 7,951,081 shares.
- Auditor Ratification: Citrin Cooperman & Company, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document serves as a disclosure of the voting results and the effective date of the charter amendment (June 26, 2019).
Investor Verification Checklist
- Verify the impact of the 25,000,000 share increase on potential future dilution.
- Review the Definitive Proxy Statement (Schedule 14A) for details on the Alto Opportunity Master Fund transaction and the terms of the 2014 Plan amendment.
- Confirm the terms of the newly filed Certificate of Amendment (Exhibit 3.1) and the Third Amended and Restated 2014 Long-Term Incentive Equity Plan (Exhibit 10.1).
- Monitor the company's compliance with Nasdaq Listing Rule 5635 following the approved share issuance.